Unknown

Dataset Information

0

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis.


ABSTRACT: Background:There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating second-line treatment in these patients. Methods:A search of MEDLINE and EMBASE identified studies reporting survival and/or response data for patients with EP-PD-NEC receiving second-line therapy. Association between various factors (age, gender, ECOG performance status, primary tumour location, morphology, Ki-67, treatment and grade 3/4 haematological toxicity) and response rate (RR), progression-free (PFS) and overall survival (OS) were assessed with a mixed effects meta-regression weighted by individual study sample size. Due to a small sample size, associations were reported quantitatively, based on magnitude of beta coefficient rather than statistical significance. Results:Of 83 identified studies, 19 were eligible, including 4 prospective and 15 retrospective studies. Analysis comprised 582 patients, with a median number of 19 patients in each study (range 5-100). Median age was 59?years (range 53-66). Median RR was 18% (range 0-50; 0% for single-agent everolimus, temozolomide, topotecan; 50% with amrubicin), median PFS was 2.5?months (range 1.15-6.0) and median OS was 7.64?months (range 3.2-22.0). Studies with a higher proportion of patients with a Ki-67>55% had lower RR (??=?-0.73) and shorter OS (??=?-0.82). Conclusion:Second-line therapy for patients with advanced EP-PD-NEC has limited efficacy and the variety of regimens used is diverse. Ki-67>55% is associated with worse outcomes. Prospective randomised studies are warranted to enable exploration of new treatment strategies.

SUBMITTER: McNamara MG 

PROVIDER: S-EPMC7222242 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis.

McNamara Mairéad G MG   Frizziero Melissa M   Jacobs Timothy T   Lamarca Angela A   Hubner Richard A RA   Valle Juan W JW   Amir Eitan E  

Therapeutic advances in medical oncology 20200427


<h4>Background</h4>There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating second-line treatment in these patients.<h4>Methods</h4>A search of MEDLINE and EMBASE identified studies reporting survival and/or response data for patients with EP-PD-NEC receiving second-line therapy. Association between various factors (age, gender, ECOG performance status, primary tumour loca  ...[more]

Similar Datasets

| S-EPMC4855772 | biostudies-literature
| S-EPMC10242623 | biostudies-literature
| S-EPMC6284856 | biostudies-other
| S-EPMC10984918 | biostudies-literature
| S-EPMC7059325 | biostudies-literature
| S-EPMC7186825 | biostudies-literature
| S-EPMC7158760 | biostudies-literature
| S-EPMC8392018 | biostudies-literature
| S-EPMC7880539 | biostudies-literature
| S-EPMC5635424 | biostudies-literature